KRAS mutations upregulate Runx1 to promote occurrence of head and neck squamous cell carcinoma
© 2023 Wiley Periodicals LLC..
Gene mutations play an important role in head and neck squamous cell carcinoma (HNSCC) by not only promoting the occurrence and progression of HNSCC but also affecting sensitivity to treatment and prognosis. KRAS is one of the most frequently mutated oncogenes, which has been reported to have a mutation rate from 1.7% to 12.7% and may lead to poor prognosis in HNSCC, but its role remains unclear. Here, we found that the KRAS mutation can promote HNSCC generation through synergism with 4-Nitroquinoline-1-Oxide(4NQO). Mechanistically, KRAS mutations can significantly upregulate Runx1 to promote oral epithelial cell proliferation and migration and inhibit apoptosis. Runx1 inhibitor Ro 5-3335 can effectively inhibit KRAS-mutated HNSCC progression both in vitro and in vivo. These findings suggest that the KRAS mutation plays an important role in HNSCC and that Runx1 may be a novel therapeutic target for KRAS-mutated HNSCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Molecular carcinogenesis - 62(2023), 9 vom: 12. Sept., Seite 1284-1294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deng, Miao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Animal model |
|---|
| Anmerkungen: |
Date Completed 21.08.2023 Date Revised 08.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mc.23563 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357247868 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357247868 | ||
| 003 | DE-627 | ||
| 005 | 20231226072156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mc.23563 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357247868 | ||
| 035 | |a (NLM)37222390 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deng, Miao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a KRAS mutations upregulate Runx1 to promote occurrence of head and neck squamous cell carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2023 | ||
| 500 | |a Date Revised 08.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Gene mutations play an important role in head and neck squamous cell carcinoma (HNSCC) by not only promoting the occurrence and progression of HNSCC but also affecting sensitivity to treatment and prognosis. KRAS is one of the most frequently mutated oncogenes, which has been reported to have a mutation rate from 1.7% to 12.7% and may lead to poor prognosis in HNSCC, but its role remains unclear. Here, we found that the KRAS mutation can promote HNSCC generation through synergism with 4-Nitroquinoline-1-Oxide(4NQO). Mechanistically, KRAS mutations can significantly upregulate Runx1 to promote oral epithelial cell proliferation and migration and inhibit apoptosis. Runx1 inhibitor Ro 5-3335 can effectively inhibit KRAS-mutated HNSCC progression both in vitro and in vivo. These findings suggest that the KRAS mutation plays an important role in HNSCC and that Runx1 may be a novel therapeutic target for KRAS-mutated HNSCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HNSCC | |
| 650 | 4 | |a KRAS | |
| 650 | 4 | |a Ro 5-3335 | |
| 650 | 4 | |a Runx1 | |
| 650 | 4 | |a animal model | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a KRAS protein, human |2 NLM | |
| 700 | 1 | |a Guo, Jiaxin |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Zihang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chi |e verfasserin |4 aut | |
| 700 | 1 | |a He, Lihong |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Zhaona |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Juan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular carcinogenesis |d 1990 |g 62(2023), 9 vom: 12. Sept., Seite 1284-1294 |w (DE-627)NLM012634956 |x 1098-2744 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:9 |g day:12 |g month:09 |g pages:1284-1294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mc.23563 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 9 |b 12 |c 09 |h 1284-1294 | ||